NeoDynamics granted a U.S. patent for its biopsy needle
STOCKHOLM – AUGUST 25, 2021, NeoDynamics AB (publ) (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announced that the Company has been granted a U.S. patent for its needle design employed in the NeoNavia FlexiPulse probe.The patent is an important milestone for the planned commercial launch in the U.S. and strengthens the protection of the NeoNavia biopsy system. The front-loaded, open-tip sampling needle is designed to enable maximum tissue yield, with minimal patient trauma. “This is exciting news for NeoDynamics. We